|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 99.81 USD | +6.05% |
|
-5.72% | +26.46% |
| 08-06 | RBC Capital Adjusts Mirum Pharmaceuticals PT to $135 From $148, Maintains Outperform Rating | MT |
| 08-05 | Mirum Pharmaceuticals, Inc., Q2 2026 Earnings Call, Aug 05, 2026 |
Chart: Technical Analysis
Technical analysis trends
| Short Term | Mid-Term | Long Term | |
|---|---|---|---|
| Trend | Bearish | Neutral | Bullish |
| Resistance | 112.59 | 128.57 | 125.59 |
| Spread/Res. | -11.28% | -22.31% | -20.46% |
| Spread/Supp. | +15.75% | +15.75% | +6.86% |
| Support | 86.3 | 86.3 | 93.48 |
MarketScreener's Technical Analysis Ratings
| Short Term Timing | |
|---|---|
| Middle Term Timing | |
| Long Term Timing | |
| RSI | |
| Bollinger Spread | |
| Unusual Volumes |
- Stock Market
- Stocks
- MIRM Stock
- Charts Mirum Pharmaceuticals, Inc.
Select your edition
All financial news and data tailored to specific country editions
